A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05394168|
Recruitment Status : Not yet recruiting
First Posted : May 27, 2022
Last Update Posted : May 27, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Advanced/Metastatic Solid Tumors or Lymphoma||Biological: HLX53||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Clinical Study to Evaluate the Safety, Tolerability, Kinetic Characteristics and Preliminary Efficacy of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma|
|Estimated Study Start Date :||September 15, 2022|
|Estimated Primary Completion Date :||August 4, 2024|
|Estimated Study Completion Date :||February 4, 2025|
The 50 mg, 150 mg, 400 mg, and 800 mg dose groups were administered once every 1 week (QW); the 1600 mg dose group was administered once every 2 weeks (Q2W); and the 2400 mg dose group was administered once every 3 weeks (Q3W).
- Adverse event [ Time Frame: Through study completion, assessed up to 2 years. ]Incidence and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 for patients receiving study drug.
- Incidence of DLT [ Time Frame: Up to 4 weeks. ]Ratio of the number of patients with DLT events in each dose group to the number of patients in the dose group during the DLT evaluation period.
- MTD [ Time Frame: Up to 4 weeks ]The maximum tolerated dose (MTD) of HLX53
- RP2D [ Time Frame: Through study completion, assessed up to 2 years. ]The recommended phase II dose (RP2D) of HLX53
- Cmax [ Time Frame: From baseline to 30 days after the last administration, assessed up to 7 months ]Peak concentration of HLX53
- Tmax [ Time Frame: From baseline to 30 days after the last administration, assessed up to 7 months ]Time to reach peak concentration of HLX53
- t1/2 [ Time Frame: From baseline to 30 days after the last administration, assessed up to 7 months ]Elimination half-life of HLX53
- TIGIT Receptor Occupancy [ Time Frame: From baseline to 30 days after the last administration，assessed up to 7 months ]TIGIT Receptor Occupancy of HLX53 on Peripheral Circulating T Cells
- ADA [ Time Frame: From baseline to 30 days after the last administration，assessed up to 7 months ]Incidence of anti-drug antibodies (ADA)
- Objective response rate (ORR) [ Time Frame: Through study completion, assessed up to 2 years. ]Percentage of patients with complete response or partial response determined by investigators according to RECIST v1.1, iRECIST 2017 (solid tumors), or Lugano 2014 (lymphoma).
- Progression-free survival (PFS) [ Time Frame: From date of the first HLX53 administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. ]PFS is defined as the time from the first administration of HLX53 to the first occurrence of disease progression or death due to any cause, whichever occurs first.
- Overall survival(OS) [ Time Frame: From date of the first HLX53 administration until the date of death from any cause, whichever came first, assessed up to 2 years. ]OS is defined as the time from the first administration of HLX53 to death due to any cause.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Voluntary participation in clinical studies, full understanding of the trial, and signing of informed consent, willingness to follow and ability to complete the study in accordance with the requirements of the trial protocol.
- histologically or cytologically confirmed advanced/metastatic solid tumors or lymphoma, failure of standard therapy, or no standard therapy.
- Age ≥ 18 years and ≤ 75 years at the time of informed consent.
- Eastern Cooperative Oncology Group (ECOG) score 0 or 1.
- At least one measurable lesion according to RECISTv1.1 or 2014 Lugano (lymphoma) response evaluation criteria.
- Life expectancy of more than three months.
- Adequate hematological function.
- Adequate liver function.
- Adequate renal function
- Adequate cardiac function.
- Male and female subjects of childbearing potential must agree to use at least 1 highly effective method of contraception during the trial and for at least 6 months after the last dose of study drug.
- Known history of serious allergy to the components of HLX53 or to any monoclonal antibody.
- Prior treatment with anti-TIGIT or antibody to the relevant target CD155, CD112, or CD113.
- Unresolved toxicity after prior antineoplastic therapy, i.e., not resolved to baseline, Grade 0-1 per NCI-CTCAE 5.0 (except alopecia).
- Coexisting unstable or controlled medical conditions.
- Spinal cord compression with clinical symptoms.
- Prior allogeneic bone marrow transplant or solid organ transplant.
- History of primary immunodeficiency.
- History of eczema or asthma that cannot be controlled by topical corticosteroids.
- History of any second malignancy within 2 years, except for curatively treated early malignancies (carcinoma in situ or stage I tumors) such as non-melanoma skin cancer, carcinoma in situ of the cervix, localized prostate cancer, ductal carcinoma in situ of the breast, papillary thyroid cancer.
- Vaccination with a live attenuated vaccine within 4 weeks prior to the first dos.e
- Use of immunosuppressive drugs within 2 weeks prior to initial administration.
- Received major surgery, anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy, immunotherapy or biological therapy) within 4 weeks prior to the first dose.
- Known to have active infectious disease such as active HBV, HCV infection.
- History of human immunodeficiency virus (HIV) infection.
- Pregnancy or lactation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05394168
|Contact: Xiongxiong Liu||+8618832503398||Xiongxiong_Liu@henlius.com|
|Principal Investigator:||Jian Zhang||Fudan University|
|Responsible Party:||Shanghai Henlius Biotech|
|Other Study ID Numbers:||
|First Posted:||May 27, 2022 Key Record Dates|
|Last Update Posted:||May 27, 2022|
|Last Verified:||May 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms by Histologic Type
Immune System Diseases